Aravax Information

View Top Employees from Aravax

Aravax is a clinical stage biotechnology company dedicated to revolutionising the treatment of food allergy by developing next-generation, disease-modifying peptide-based immunotherapies that are safer and more convenient than existing approaches. Its lead programme is PVX108, in clinical development for the treatment of peanut allergy.

Website	https://www.aravax.com.au/
Revenue	$9 million
Funding	$9.7 million
Employees	20 (5 on RocketReach)
Founded	2015
Address	Level 9, 31 Queens Street, Melbourne, Victoria 3000, AU
Phone	+61 3 9657 0700
Technologies	JavaScript , HTML , Twitter +7 more (view full list)
Industry	Biotechnology, Biotechnology Research, Pharmaceuticals, Healthcare, Science and Engineering, Health Care, Drug Manufacturing & Research, Wellness
Keywords	Clinical Stage Biotechnology, Therapeutic Peptides, Allergy Immunotherapy, Novel Therapy, Food Allergy Treatment, Biotechnology, Biopharmaceutical, Immunotherapy, Clinical Trials, Drug Development, Allergy Research, Health Solutions, Patient Care
Competitors	Pfizer, Sanofi, GSK, AstraZeneca, Moderna Therapeutics, Novavax, Immunocore, Zydus Cadila Healthcare Limited, INOVIO Pharmaceuticals, Inc., CanSino Biologics Inc.康希诺生物 +36 more (view full list)
SIC	SIC Code 873 Companies, SIC Code 87 Companies
NAICS	NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 541713 Companies, NAICS Code 54171 Companies